Ligand Pharmaceuticals Incorporated Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $0.83 | $0.83 | $0.83 |
| Q2 2024 | 3 | $1.06 | $1.06 | $1.06 |
| Q3 2024 | 5 | $0.92 | $1.94 | $1.35 |
| Q4 2024 | 3 | $1.43 | $1.43 | $1.43 |
| Q1 2025 | 4 | $1.44 | $1.44 | $1.44 |
| Q2 2025 | 4 | $1.48 | $1.48 | $1.48 |
| Q3 2025 | 4 | $1.60 | $1.60 | $1.60 |
| Q4 2025 | 4 | $1.87 | $1.87 | $1.87 |
Ligand Pharmaceuticals Incorporated Earnings Date And Information
Ligand Pharmaceuticals Incorporated last posted its earnings results on Tuesday, August 6th, 2024. The company reported $1.4 earnings per share for the quarter, topping analysts' consensus estimates of $1.1 by $0.3. The company had revenue of 41.53 M for the quarter and had revenue of 131.31 M for the year. Ligand Pharmaceuticals Incorporated has generated $3 earnings per share over the last year ($2.94 diluted earnings per share) and currently has a price-to-earnings ratio of 50.56. Ligand Pharmaceuticals Incorporated has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based on prior year's report dates.
Ligand Pharmaceuticals Incorporated Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/07/2024 | Q2 2024 | -$2.88 | $33.04 M | $41.53 M | ||
| 05/08/2024 | Q1 2024 | $4.86 | $30.98 M | |||
| 02/29/2024 | Q4 2023 | $1.04 | $28.10 M | |||
| 11/09/2023 | Q3 2023 | -$0.74 | $27.22 M | $32.87 M | ||
| 08/09/2023 | Q2 2023 | $0.13 | $24.74 M | $26.37 M | ||
| 05/08/2023 | Q1 2023 | $2.46 | $43.98 M | |||
| 02/28/2023 | Q4 2022 | -$0.86 | $50.38 M | |||
| 11/08/2022 | Q3 2022 | $0.02 | $38.32 M | $66.09 M | ||
| 08/09/2022 | Q2 2022 | -$0.05 | $37.73 M | $57.42 M | ||
| 05/09/2022 | Q1 2022 | -$0.92 | $45.69 M | |||
| 02/28/2022 | Q4 2021 | -$0.30 | $72.47 M | |||
| 11/09/2021 | Q3 2021 | $1.02 | $0.82 | -0.2 | $58.74 M | $64.84 M |
| 08/02/2021 | Q2 2021 | $1.84 | $71.41 M | $84.68 M | ||
| 05/06/2021 | Q1 2021 | $1.10 | $55.15 M | |||
| 02/24/2021 | Q4 2020 | $0.36 | $69.99 M | |||
| 11/06/2020 | Q3 2020 | -$0.42 | $45.09 M | $41.85 M | ||
| 08/07/2020 | Q2 2020 | $1.38 | $29.96 M | $41.42 M | ||
| 05/08/2020 | Q1 2020 | -$1.46 | $33.16 M | |||
| 02/27/2020 | Q4 2019 | -$0.43 | $27.00 M | |||
| 11/08/2019 | Q3 2019 | -$0.81 | $22.36 M | $24.81 M |
Ligand Pharmaceuticals Incorporated Earnings: Frequently Asked Questions
-
When is Ligand Pharmaceuticals Incorporated's earnings date?
Ligand Pharmaceuticals Incorporated has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates.
-
Did Ligand Pharmaceuticals Incorporated beat their earnings estimates last quarter?
In the previous quarter, Ligand Pharmaceuticals Incorporated (:LGND) reported $1.4 earnings per share (EPS) to beat the analysts' consensus estimate of $1.1 by $0.3.
-
How can I listen to Ligand Pharmaceuticals Incorporated's earnings conference call?
The conference call for Ligand Pharmaceuticals Incorporated's latest earnings report can be listened to online.
-
How can I read Ligand Pharmaceuticals Incorporated's conference call transcript?
The conference call transcript for Ligand Pharmaceuticals Incorporated's latest earnings report can be read online.
-
How much revenue does Ligand Pharmaceuticals Incorporated generate each year?
Ligand Pharmaceuticals Incorporated (:LGND) has a recorded annual revenue of $131.31 M.
-
How much profit does Ligand Pharmaceuticals Incorporated generate each year?
Ligand Pharmaceuticals Incorporated (:LGND) has a recorded net income of $131.31 M. Ligand Pharmaceuticals Incorporated has generated $3.02 earnings per share over the last four quarters.
-
What is Ligand Pharmaceuticals Incorporated's price-to-earnings ratio?
Ligand Pharmaceuticals Incorporated (:LGND) has a price-to-earnings ratio of 50.56 and price/earnings-to-growth ratio is -0.89.
